Bristol Myers-Squibb co-led the genomic testing technology provider's series B round, which will support the expansion of its cancer tests to patients.
Pharmaceutical company Bristol Myers-Squibb co-led a $75 series B round for US-based genomic data technology developer Personal Genome Diagnostics (PGDx) yesterday with venture capital firm New Enterprise Associates (NEA).
Inova Strategic Investments, a subsidiary of care provider Inova Health System, also took part in the round, alongside Co-win Healthcare Fund, Helsinn Investment Fund, Windham Venture Partners, Maryland Venture Fund and undisclosed existing investors.
Founded in 2010, PGDx is developing tissue-based and liquid biopsy genomic testing products that will help laboratories…
